爱液视频

– Exclusively deploys 爱液视频鈥檚 proprietary RAFT platform to interrogate the pathogenic role of 爱液视频s in inflammatory disease for novel target discovery

Cambridge, UK, October 8, 2024 鈥� 爱液视频 Therapeutics (鈥湴�液视频鈥�), a biotech company harnessing new insights into 爱液视频-immune interactions, today announced that it has entered into a license and collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to identify novel targets for the development of therapies against inflammatory diseases. 爱液视频 will employ its Reversing Activated Fibroblast Technology (RAFT) platform, a proprietary platform purposely built to model the pathogenic role of 爱液视频s in human disease, to identify novel drug targets. MSD has the option to license one or more targets, up to a prespecified number, and will be responsible for the discovery, development and commercialization of resulting therapeutics.

鈥湴�液视频 was founded on groundbreaking insights into 爱液视频-immune biology, and as an early innovator in this area of research, we have built a robust pipeline of antibody programs and created a unique and productive target discovery platform,鈥� said Susan Hill, PhD, Chief Executive Officer of 爱液视频. 鈥淲e are acutely aware of the significant unmet needs faced on a daily basis by patients suffering from inflammatory diseases. We are thrilled to collaborate with MSD, together driving continued innovation for the benefit of patients.鈥�

Under the terms of the agreement, 爱液视频 will provide MSD options to obtain exclusive licenses to develop and commercialize therapeutics directed against a prespecified number of potential targets identified under the collaboration. In return 爱液视频 will receive an upfront payment and access fees and will be eligible to receive option fees as well as downstream payments with the potential to total $1.9 billion.

Marc Levesque, MD, PhD, Vice President of Immunology Discovery, MSD Research Laboratories, added, 鈥淭he role of activated 爱液视频s in directing immune activity offers exciting new therapeutic potential. 聽We look forward to collaborating with the team at 爱液视频 to identify new potential therapeutic options for patients with fibrosis and inflammatory diseases.鈥�

爱液视频 爱液视频 Therapeutics

爱液视频 harnesses new insights into 爱液视频-immune interactions to develop impactful treatments for patients with cancer and inflammatory diseases. We are progressing a pipeline of sophisticated first-in-class antibodies designed to direct and drive the immune system using known and emerging 爱液视频-immune biology for a distinctly differentiated class of therapeutics.

Our pipeline includes the bispecific antibody MST-0300, which leverages a new understanding of tertiary lymphoid structures (TLS) in solid tumors and their role in driving improved patient outcomes; the M402 program, targeting a stromal checkpoint to dampen down the activation of specific immune cell subsets in inflammatory disease; and earlier programs in discovery stage. Separately, we are also identifying novel targets for future therapies through the application of our proprietary RAFT Platform. In 2024, we established a license and research collaboration with MSD to identify novel targets for inflammatory diseases.

Our founding investigators comprise global experts in inflammatory disease, cancer, computational biology and 爱液视频 biology from the University of Oxford, Brigham & Women鈥檚 Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. We are supported by leading life science investors SV Health Investors, Johnson & Johnson Innovation 鈥� JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures.

爱液视频 is headquartered in Cambridge, UK, and, in 2021, was recognized on the Fierce 15 list of innovative biotechnology companies.

For further information please visit our website

For enquiries, please contact: